Edwards Lifesciences Corporation revised earnings guidance for the full year of 2022. For total Edwards, the company now expects full year 2022 sales of $5.35 to $5.55 billion. The company now expects full year adjusted EPS guidance at the bottom end of its original guidance range of $2.50 to $2.65, representing double-digit growth over 2021.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
87.98 USD | +0.59% | -1.30% | +15.38% |
05-23 | Some of the biggest splits in Corporate America | RE |
05-22 | Citigroup Upgrades Edwards Lifesciences to Buy From Neutral, Adjusts Price Target to $105 From $98 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.38% | 53.02B | |
+10.03% | 223B | |
+13.59% | 195B | |
+20.01% | 144B | |
+30.83% | 111B | |
+2.05% | 65.01B | |
+3.96% | 50.45B | |
+8.37% | 44.15B | |
+3.27% | 36.45B | |
+23.97% | 31.33B |
- Stock Market
- Equities
- EW Stock
- News Edwards Lifesciences Corporation
- Edwards Lifesciences Corporation Revises Earnings Guidance for the Full Year of 2022